Enoblituzumab - MacroGenics

Drug Profile

Enoblituzumab - MacroGenics

Alternative Names: MGA-271

Latest Information Update: 16 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD276 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer

Most Recent Events

  • 07 May 2018 MacroGenics completes enrolment in its phase I trial for Melanoma, Head and neck Cancer, Non small cell lung cancer and Urogenital cancer in USA (NCT02475213)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Phase-I clinical trials in Solid tumours (In adolescents, In children, In infants, In adults, Second-line therapy or greater) in USA (IV) (NCT02982941)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top